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Introduction: Osteoarthritis (OA) is a whole joint disease, and characterized by progressive degradation of articular
cartilage, synovial hyperplasia, bone remodeling and angiogenesis in various joint tissues. Exosomes are a type of
microvesicles (MVs) that may play a role in tissue-tissue and cell-cell communication in homeostasis and diseases.
We hypothesized that exosomes function in a novel regulatory network that contributes to OA pathogenesis and
examined the function of exosomes in communication among joint tissue cells.
Methods: Human synovial fibroblasts (SFB) and articular chondrocytes were obtained from normal knee joints.
Exosomes isolated from conditioned medium of SFB were analyzed for size, numbers, markers and function. Normal
articular chondrocytes were treated with exosomes from SFB, and Interleukin-1β (IL-1β) stimulated SFB. OA-related
genes expression was quantified using real-time PCR. To analyze exosome effects on cartilage tissue, we performed
glycosaminoglycan release assay. Angiogenic activity of these exosomes was tested in migration and tube formation
assays. Cytokines and miRNAs in exosomes were analyzed by Bio-Plex multiplex assay and NanoString analysis.
Results: Exosomes from IL-1β stimulated SFB significantly up-regulated MMP-13 and ADAMTS-5 expression in articular
chondrocytes, and down-regulated COL2A1 and ACAN compared with SFB derived exosomes. Migration and tube
formation activity were significantly higher in human umbilical vein endothelial cells (HUVECs) treated with the
exosomes from IL-1β stimulated SFB, which also induced significantly more proteoglycan release from cartilage
explants. Inflammatory cytokines, IL-6, MMP-3 and VEGF in exosomes were only detectable at low level. IL-1β, TNFα
MMP-9 and MMP-13 were not detectable in exosomes. NanoString analysis showed that levels of 50 miRNAs were
differentially expressed in exosomes from IL-1β stimulated SFB compared to non-stimulated SFB.
Conclusions: Exosomes from IL-1β stimulated SFB induce OA-like changes both in vitro and in ex vivo models.
Exosomes represent a novel mechanism by which pathogenic signals are communicated among different cell types
in OA-affected joints.Introduction
Osteoarthritis (OA) is a highly prevalent disease in the
middle-aged and elderly population worldwide. Patho-
genesis has not been elucidated completely, and disease-
modifying treatment and prevention are presently not
available. OA risk factors include aging, acute or chronic
mechanical stress, joint trauma, and metabolic disorders* Correspondence: katotomohiro11@gmail.com
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unless otherwise stated.[1,2]. These factors impair the homeostatic balance be-
tween cartilage extracellular matrix (ECM) degradation
and repair. OA is a whole-joint disease and involves all
joint tissues including cartilage, subchondral bone, me-
nisci, ligaments and muscles. Joint inflammation at vary-
ing intensity is also present and contributes to the
chronic joint tissue remodeling process and to pain, the
main subjective symptom in OA patients [2-6]. The
homeostatic balance of all joint tissues is regulated by
intracellular molecules such as kinase cascades, autoph-
agy, and transcription factors, epigenetic mechanisms,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cytokines, hormones and mechanical stress [7,8].
Synovial inflammation and angiogenesis are important
contributors to OA pathogenesis [3,9-11]. Synovitis has
been demonstrated to correlate with OA symptom se-
verity, and hormonal factors such as cytokines, and
chemokines are important for crosstalk among joint tis-
sues [3,12]. These mediators play a role in the develop-
ment of inflammation and induce catabolic changes in
joint tissues [3,11,13,14]. Increased angiogenesis is also
observed in OA-affected ligaments, menisci and sub-
chondral bone [5,6,15].
Most nucleated cells release microvesicles (MVs),
which range from 30 to 1,000 nm in diameter, and can
be found in body fluids such as blood, urine, breast milk,
and saliva [16-18]. MVs are also present in rheumatoid
arthritis (RA) synovial fluids and can originate from
granulocytes, monocytes, and other immune cells. These
MVs modulate the release of chemokines and cytokines
in synovial fibroblasts (SFB) [19-21]. The MVs derived
from OA chondrocytes display annexins II, V, and VI,
which play an important role in pathological mineral
formation in OA [22-24]. Exosomes are one type of MV
of endocytic origin released to the extracellular environ-
ment. These small particles, of about 30 to 200 nm, are
derived from the fusion of multivesicular bodies to
plasma membranes, and are morphologically distinct
from larger secreted MVs [18,25]. Exosomes can contain
mRNA, microRNA and protein [26] and function in
cell-to-cell communication as carriers of genetic infor-
mation, and are associated with the pathogenesis of vari-
ous diseases [19,27]. Although release of MVs from SFBs
has been reported [21,28,29], the effects of exosomes
from OA synovial tissues on articular chondrocytes re-
main unknown. We hypothesized that exosomes func-
tion in a novel regulatory network that contributes to
OA and elucidate in the present study the in vitro and
ex vivo production, and the function of exosomes in the
interaction between SFB and articular chondrocytes.
Materials and methods
Human tissues and cell culture
Studies were approved human subjects/ethics protocols by
Scripps Research Institute Human Subjects Institutional
Review Boards. Normal human knee synovial fibroblasts
and chondrocytes were isolated from autopsy donors as
leftover de-identified material and with no interactions with
subjects, and therefore with no informed consent required.
Human SFB and articular chondrocytes were cultured as
described previously [30] in DMEM containing 10% FBS,
and 1% penicillin/streptomycin at 37°C in a humidified at-
mosphere of 5% CO2. Experiments with SFB were carried
out at passages 4 to 6. Experiments with normal human ar-
ticular chondrocytes were carried out at passage 1.Preparation of conditioned medium and isolation of
exosomes
Human SFB were plated at 2 × 105 per well into 6-well
plates with DMEM containing 10% FBS and 1% antibiotics
at 37°C under 5% CO2. After reaching confluence, the cells
were treated with DMEM containing recombinant human
IL-1β (1 ng/mL; Pepro Tech NJ, USA), and incubated for
24 h. The SFB were washed three times with DMEM, and
the medium was switched to fresh DMEM containing 10%
FBS (2 mL). After incubation for 24 h, the SFB conditioned
media (2 mL/well) were collected and cells were washed
with PBS, and total RNA was isolated with TRIzol reagent
(Life Technologies). The most widely accepted method for
exosome isolation is ultracentrifugation. Recently, however,
several alternate methods that are more standardized and
efficient have been developed. In the present study, we
used conventional ultracentrifugation and ExoQuick™ re-
agent kit (System Biosciences CA, USA) for isolation of
exosomes [31-33], because these methods did not show a
detectable difference in the type of exosomes obtained
when applied to supernatants from cultured cells. The
SFB-conditioned media (2 mL/well) were centrifuged for
15 minutes at 2380 × g to remove debris, and then further
ultracentrifuged for 70 minutes at 110,000 × g (Optima TL
ultracentrifuge, Beckman Coulter, Brea, CA, USA). The su-
pernatants were collected as exosome-depleted condi-
tioned media (CM-exo). The purified exosomes were
resuspended in DMEM for direct use in subsequent
experiments.
Size distribution analysis by tunable resistive pulse sensor
(TRPS)
Exosomes isolated by ultracentrifugation were resuspended
in 100 mM KCl and 40 mM HEPES. The measurements of
particle size and number were performed on an Izon
qNano system by TRPS technology (Izon Science, Ltd
Christchurch, New Zealand) as previously reported [34,35].
Immunoblotting for exosome markers
Exosomes and proteins isolated from cells were sus-
pended in sample buffer solution (not containing 2-
mercaptoethanol; Wako, Japan). Proteins were separated
on Mini-PROTEAN TGX gels (Bio-Rad Laboratories,
Hercules, CA, USA) and transferred to a polyvinylidene
fluoride (PVDF) membrane by Trans-Blot Turbo™ trans-
fer system (Bio-Rad Laboratories). Mouse anti-human
CD9 (1:200, BD Biosciences), anti-CD81 (1:200, Santa
Cruz Biotechnology, Inc), and anti-flotillin-1 (1:500, BD
Biosciences) were used as the primary antibodies. Goat
anti-mouse IgG-HRP (Santa Cruz, sc-2005) was used as
the secondary antibody. Chemiluminescence signal was
detected with Immno-enhancer (WAKO, Japan) using
the ImageQuant LAS-4000 mini luminescent image
analyzer (FUJIFILM, Japan).
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from SFB
The measurements of cytokines (IL-1β, IL-6, TNFα,
VEGF) and MMPs (MMP-3, -9, -13) within exosomes,
CM-exo and conditioned media (CM) from SFB were per-
formed by Bio-Plex suspension assay system (Bio-Rad
Laboratories) as per the manufacturer’s protocol. Exosomes
and CM-exo were isolated from conditioned medium by
ultracentrifugation and the ExoQuick™ reagent kit.
Treatment of normal human articular chondrocytes with
SFB-derived exosomes
Human articular chondrocytes were seeded at 5 × 104/
well into 24-well plates in DMEM containing 10% FBS,
and cultured for 24 h. After the cells became confluent,
exosome suspensions in DMEM and CM-exo were
added. After incubation for 24 h, total RNA was ex-
tracted from chondrocytes using TRIzol reagent (Life
Technologies).
Quantitative real-time PCR
Complementary DNA (cDNA) was synthesized using
500 ng of total RNA with Superscript VILO kit (Invitrogen)
according to the manufacturer’s protocol. Real-time PCR
assay was performed using TaqMan Gene Expression
Assays probes (Life Technologies) for COL2A1 (Hs01
064869_m1), ACAN (Hs00202971_m1), MMP-13 (Hs00
233992_m1), ADAMTS-5 (Hs00199841_m1), IL-6 (Hs00
985639_m1), MMP-3 (Hs00233962_m1), IL-1β (Hs001
74097_m1), TNFα (Hs00174128_m1) and GAPDH (Hs027
58991_m1). The expression levels for each gene were
assessed relative to the expression of GAPDH. The ΔΔCt
method was used for analysis of real-time PCR data.
Proteoglycan release assay
Femoral heads were harvested from 4-week-old wild-
type mice and incubated at 37°C for 72 h in 48-well
plates. Each well contained 500 μl of DMEM with
10% FBS and 1% penicillin/streptomycin. The cartilage
samples were washed three times, and cultured at
37°C for an additional 72 h in 500 μl of serum-free
DMEM containing exosomes isolated by ExoQuick™
from SFB with IL-1β or without IL-1β. The assay was
performed in at least three independent experiments
with duplicate wells using SFB-derived exosomes. The
concentration of the released glycosaminoglycan in the
conditioned medium from cartilage was measured using
the Blyscan Glycosaminoglycan assay kit (Biocolor UK)
as per the manufacturer’s protocol.
Endothelial cell migration assay
Human umbilical vein endothelial cells (HUVECs) were pur-
chased from Lonza and cultured with endothelial basal
medium-2 (EBM-2) (Lonza Basel, Switzerland). Themigration of HUVECs was assessed using aTranswell Boyden
Chamber (8-μm pore size) (BD Bioscience). HUVECs sus-
pended in 0.5 mL of serum-free DMEM containing exo-
somes were added at 2 × 104 cells/well to the 24-well upper
chamber, and 0.75 mL of DMEM was added to the bottom
well. After incubation for 4 h, the lower side of the filter
was washed with PBS and fixed with 4% paraformaldehyde.
The migrated cells were quantified as the number of cell
nuclei stained with 4',6-diamidino-2-phenylindole (DAPI).
Tube formation assay
HUVECs were pre-cultured overnight in DMEM with
0.25% FBS and then reseeded at a density of 2.5 × 104
cells/well in 48-well plates pre-coated with Matrigel
Matrix (BD Biosciences). HUVECs were treated with
DMEM with 0.25% FBS containing, vascular endothelial
growth factor (VEGF) (50 ng/mL as positive control),
IL-1β (1 ng/mL) and exosomes for 4 h. Tube length was
measured by means of Image J analysis of digital images.
miRNA analysis in exosomes from SFB-conditioned medium
Exosomes were isolated from 15 mL of conditioned
medium from SFB seeded at 1.5 × 106 cells/15 cm plate
by ultracentrifugation. Small RNA was purified from exo-
somes using the mirVana isolation kit (Life Technologies).
The small RNA concentration and quality were deter-
mined by BioAnalyzer 2100 (Agilent Technologies, Santa
Clara, CA, USA), and at least 5 ng RNA were then used as
input for the nCounter Human miRNA Expression Assay
kit (NanoString Technologies, Seattle, WA, USA). The
miRNA expression profiles were analyzed according to
manufacturer’s instructions.
Statistical analysis
The data were analyzed using the Mann-Whitney U-test
and Steel test to analyze statistical differences. Differences
were considered statistically significant at a P-value <0.05
(*P <0.05; **P <0.01).
Results
Effect of IL-1β on gene expression in SFB
IL-1β is one of the critical mediators of OA, and IL-1β
stimulation of SFB causes OA-like gene expression pat-
terns [10,11,13]. To examine the gene expression
changes by the IL-1β treatment in host cells (SFB) of
exosomes, we performed real-time PCR for MMP-3,
MMP-13, IL-1β, IL-6, TNFα and VEGF in SFB. In re-
sponse to IL-1β stimulation, the expression of MMP-3,
MMP-13, IL-1β, IL-6, and VEGF were significantly in-
creased compared with non-stimulated SFB (Figure 1).
Exosomes in IL-1β-stimulated SFB-conditioned medium
To examine whether the secretion of exosomes from SFB
is influenced by the IL-1β treatment, we analyzed the size
Figure 1 IL-1β induced gene expression in synovial fibroblasts (SFB). SFB (six different preparations from six different donors) were cultured
with DMEM containing recombinant human IL-1β (1 ng/ml) for 24 h. The SFB were washed three times with DMEM, and the medium was
switched to fresh DMEM containing 10% FBS. After incubation for 24 h, gene expression was analyzed by real-time PCR. Data are the means ±
standard error of the mean. Comparison of mean values was performed by Mann-Whitney U-test; *P <0.05 versus non-stimulated SFB. NS, no
significant change; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
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somes from conditioned medium by ultracentrifugation.
The size distribution of particles derived from SFB
with IL-1β or without IL-1β was very similar, and the
major peak in particle size was 60 to 80 nm and the
overall size distribution ranged between 60 and 200 nm
(Figure 2A). The numbers of nanoparticles including
exosomes derived from IL-1β-stimulated SFB-conditioned
medium were significantly increased compared with non-
stimulated SFB-conditioned medium (Figure 2B). Several
molecules, including the tetraspanins (CD9, CD63,
CD81) and flotillin-1 are enriched in exosomes [25,36].
We confirmed the presence of exosome marker proteins
in conditioned medium from SFB (Figure 2C). Exo-
some markers (CD9, CD81, flotillin-1) in conditioned
medium from IL-1β-treated SFB were also increased
compared with SFB-conditioned medium without IL-1β
(Figure 2C). Next, to examine cytokines and MMPs in
exosomes from IL-1β-stimulated SFB, the concentration
of cytokines was measured in CM, exosomes, and
supernatant after ultracentrifugation (CM-exo) using
Bio-Plex Multiplex assay. Inflammatory cytokines, IL-6,
angiogenic factor, VEGF and MMP-3 were included in
CM and CM-exo from non-stimulated SFB, and were
increased in CM and CM-exo from IL-1β-stimulated
SFB. However, IL-6, MMP-3 and VEGF levels in exo-
somes were lower than in CM and CM-exo (Figure 3).
IL-1β, TNFα, MMP-9 and MMP-13 were not detectable
in CM, CM-exo and exosomes.Exosomes from IL-1β-stimulated SFB induce OA-related
gene expression patterns in articular chondrocytes
To elucidate the effects of exosomes from IL-1β-stimulated
SFB, exosomes and CM-exo were added to articular chon-
drocytes. After incubation for 24 h with each medium, we
examined the expression of OA-related genes by real-time
PCR. Exosomes and CM-exo from IL-1β-stimulated SFB
significantly upregulated MMP-13 expression compared
with exosomes from non-stimulated SFB. In contrast,
the expression of ACAN was significantly downregulated
(Figure 4A). TNFα expression was significantly increased by
exosomes from IL-1β-stimulated SFB, but not by CM-exo
from IL-1β-stimulated SFB (data not shown). The changes
of MMP-13, and ADAMTS-5 expression in articular chon-
drocytes with CM-exo from IL-1β-stimulated SFB were sig-
nificantly greater than those observed with exosomes
(Figure 4A). The expression of VEGF was not increased in
articular chondrocytes treated with exosomes and CM-exo
from IL-1β-stimulated SFB (data not shown). These find-
ings suggest that the exosomes from IL-1β stimulated SFB
induce expression of OA-related genes in articular chon-
drocytes. Isolated exosomes fraction by ExoQuick™ also sig-
nificantly induced OA-related gene expression patterns in
articular chondrocytes (Figure 4B).
Proteoglycan release from cartilage explants by
exosomes from IL-1β-stimulated SFB
To determine whether IL-1β-stimulated SFB-derived exo-
somes induce cartilage catabolic changes, we quantified
Figure 2 Exosomes derived from synovial fibroblast (SFB)-conditioned medium. (A) The size distribution of the particles in the
ultracentrifugation pellet was measured with the qNano system. The major peak in particle size was at 60 to 80 nm and overall size distribution
ranged between 60 and 200 nm. (B) The numbers of nanoparticles, including exosomes, isolated from IL-1β-stimulated SFB were significantly
higher than the numbers in non-stimulated SFB (NSFB). Data are the means ± standard error of the mean. Comparison of mean values was
performed by Mann-Whitney U-test; *P <0.05 versus non-stimulated SFB. (C) Immunoblotting of exosome markers, CD9, CD81, and flotillin-1,
in isolated exosomes from IL-1β-stimulated SFB or non-stimulated SFB. Flot, flottilin-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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plants. Exosomes from IL-1β stimulated SFB significantly
increased proteoglycan release compared with exosomes
from non-stimulated SFB (Figure 5).
SFB derived exosomes induce angiogenesis
To examine the effects of exosomes from IL-1β-
stimulated SFB on angiogenic activity, migration and
tube formation assays were performed with HUVECs.
Migration activity in HUVECs treated with exosomes
from IL-1β-stimulated SFB was significantly higher than
with exosomes from non-stimulated SFB (Figure 6A).
The same pattern of differences was observed in the tubeformation assay (Figure 6B). Addition of IL-1β did not in-
crease migration and tube formation (Figure 6A, B). These
results suggest that exosomes from IL-1β-stimulated SFB
contain angiogenic signals.
miRNA in exosomes from OA-like SFB
To further examine whether miRNAs in exsomes induce
OA-like changes, we characterized miRNA in exosomes
using the NanoString system, comparing IL-1β-stimulated
SFB with non-stimulated SFB. The IL-1β treatment had
a major effect on miRNA expression in SFB, increasing
the expression of 340 miRNA and decreasing 24 of them:
11 miRNA in exosomes were increased and 39 were
Figure 3 IL-6, matrix metalloproteinase (MMP)-3 and vascular endothelial growth factor (VEGF) in exosomes derived from
IL-1β-stimulated synovial fibroblasts (SFB). The concentration of pro-inflammatory cytokines (IL-1β, IL-6, TNFα), angiogenic factor (VEGF) and
cartilage degradation enzymes (MMPs) was measured in CM, exosomes, and CM-exo from IL-1β stimulated SFB using Bio-Plex assays. CM and
CM-exo contained significant amounts of IL-6, VEGF and MMP-3. However, exosomes contained significantly lower IL-6, VEGF and MMP-3 levels than
CM or CM-exo. Data are the means ± standard error of the mean. CM, conditioned medium; CM-exo, exosome-depleted conditioned medium;
U Exo, exosome isolated by ultracentrifugation method; Q Exo, exosome isolated by ExoQuick™ reagent.
Figure 4 The effect of IL-1β-stimulated synovial fibroblast (SFB)-derived exosomes on normal articular chondrocytes. (A) Articular
chondrocytes were treated with fresh-DMEM, exosomes from non-stimulated SFB or exosomes from IL-1β-stimulated SFB. Exosomes from SFB
were isolated by ultracentrifugation from six different donors. The expression of osteoarthritis-related genes was analyzed by real-time PCR. Matrix
metalloproteinase (MMP)-13 was significantly upregulated, and ACAN significantly downregulated by exosomes from IL-1β stimulated SFB. Data
are the means ± standard error of the mean (SEM). Comparison of mean values was performed by the Steel test; **P <0.01 versus Exo-IL. MD,
fresh DMEM with 10% FBS; Exo -IL, exosomes from non-stimulated SFB; Exo + IL, exosomes from IL-1β stimulated SFB. (B) Exosomes were isolated
from SFB-conditioned media (three separate cell preparations and experiments) using ExoQuick™ reagent. Exosomes from IL-1β-stimulated SFB
significantly downregulated COL2A1 and ACAN expression and upregulated MMP-13 and ADAMTS-5 expression in articular chondrocytes. An
exosome layer was isolated using ExoQuick™ reagent from fresh-DMEM and was used as control. Data are the means ± SEM. Comparison of mean
values was performed by the Steel test; **P <0.01 versus Exo -IL. Cont, control.
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Figure 5 Effect of synovial fibroblast (SFB)-derived exosomes in
cartilage explants. Mouse femoral head cartilage explants cultured
with exosomes from non-stimulated SFB or IL-1β-stimulated SFB.
Exosomes were isolated from SFB-conditioned medium using
ExoQuick™ reagent. Proteoglycan release into the conditioned medium
from cartilage was analyzed. Exosomes from IL-1β-stimulated SFB
induced significantly more proteoglycan release than exosomes from
non-stimulated SFB. Data are the means ± standard error of the mean.
Comparison of mean values was performed by the Steel test; *P <0.05
versus control (Cont). Cont, isolated exosomes from fresh-DMEM with
10% FBS; Exo -IL-1β, exosomes from non-stimulated SFB; Exo + IL-1β,
exosomes from IL-1β-stimulated SFB.
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miRNA in both IL-1β-stimulated SFB and their exosomes
were five miRNA, and six miRNA selectively presented in
exosomes (Figure 7B). Differentially expressed miRNA in
exosomes are shown as the ratio of miRNA in exosomes
from IL-1β-stimulated SFB to miRNA in exosomes from
non-stimulated SFB (Figure 7C).
Discussion
This study focused on exosomes as a new secretion and
communication factor in OA. IL-1β is one of the most
prominent mediators of cartilage degradation and joint
inflammation [11,13,37]. Therefore, we used IL-1β to
simulate an OA environment in the SFB and their con-
ditioned medium. Recently, extracellular vesicles, includ-
ing exosomes, have attracted attention as new players in
cell-to-cell communication [26,38-40]. Exosomes may
directly stimulate target cells through receptor-mediated
interactions or may transfer from the host cell to the re-
cipient cell various bioactive molecules such as proteins,
mRNA and miRNA [27]. Exosomes are defined as small
vesicles between 30 and 100 nm in diameter [18]. Al-
though they are distinguished from other MVs based on
their size, some differences are still unclear. Exosomes
are formed intracellularly within multivesicular bodies
and they have common surface components, such CD9,
CD63, CD81, and flotillin-1 [25,36]. Although MVs (100
to 1,000 nm in diameter) are larger than exosomes, they
are shed from the plasma membrane surface. MVs thatare 200 to 700 nm in diameter and are released from
lymphocytes and monocytes induce MMPs and cytokine
expression by SFB [21]. The exosomes isolated from
SFB-conditioned media ranged in size mainly between
60 nm and 120 nm, and expressed exosome markers, in-
cluding CD9, CD81 and flotillin-1. Furthermore, the re-
lease of exosomes was increased by IL-1β stimulation to
SFB. Although the mechanisms of exosome release from
cells remain incompletely understood, the release of exo-
somes has been shown to be affected by the pathological
environment and culture condition [41-43]. These re-
ports suggest that the OA pathological tissue environ-
ment regulates the release of exosomes from joint cells,
including SFB. In this regard, exosomes may also reflect
the specific disease environment. Therefore, exosomes
have potential as diagnostic markers, and also offer
insight into new regulatory pathways of pathogenesis.
MMPs, inflammatory cytokines and growth factors
cause OA-like changes in joint tissues [10,11,13]. IL-1β-
stimulated SFB and SFB from osteoarthritic joints can
secrete a variety of cytokines and growth factors in vivo
and in vitro, including MMPs, IL-6 and VEGF, which
is a major factor in inflammation and angiogenesis
[11,13,37]. Indeed, we showed that exosomes from IL-1β
stimulated SFB increased the expression of MMP-3, IL-
6, and VEGF. MMP-3, IL-6 and VEGF were present in
CM and CM-exo. However, their levels were signifi-
cantly lower in exosomes than in CM and CM-exo.
After ultracentrifugation for isolation of exosomes, the
supernatants were collected as CM-exo. Indeed, exo-
some markers such as CD9 and flotillin-1 were not de-
tected in CM-exo (data not shown). These results
indicate that almost IL-6 and VEGF were contained in
CM-exo after exosomes isolation by ultracentrifugation
method. Although CM-exo induced the OA-like gene
expression patterns in articular chondrocytes, exosomes
from IL-1β-stimulated SFB also induced the OA-like
gene expression patterns, and they stimulated proteogly-
can release from cartilage explants. Therefore, the OA-
like changes may be not only attributable to cytokines
and growth factors, but also to exosomes. The exosomes
from IL-1β-stimulated SFB induced expression of OA-
related genes, especially in articular chondrocytes. These
results suggest that other factors, including miRNA in
exosomes, mediate OA-like changes. Furthermore, we
showed that IL-1β-stimulated SFB-derived exosomes in-
duced angiogenic activities such as migration and tube
formation in HUVEC. Increased angiogenesis occurs in
most tissues in osteoarthritic joints, including synovium,
menisci, ligaments and subchondral bone and inhibition
of angiogenesis has been shown to be effective in models
of OA [3,9-11]. Therefore, exosomes may promote
increased angiogenesis in OA joint tissues. Taken to-
gether, SBF-derived exosomes may function as a novel
Figure 6 Effects of synovial fibroblast (SFB)-derived exosomes on angiogenic activity. SFB-derived exosomes were tested on human
umbilical vein endothelial cells (HUVEC) for stimulation of migration and tube formation. Exosomes were isolated by ExoQuick™ reagent.
(A) Migration activity was significantly higher in HUVEC treated with the exosomes from IL-1β-stimulated SFB as compared to PBS and the
exosomes from SFB without IL-1β. HUVEC migration was not induced in HUVEC by IL-1β alone. Data are the means ± standard error of the mean
(SEM). Comparison of mean values was performed by the Steel test; *P <0.05 versus control. (B) Tube length was significantly greater in HUVEC
incubated with the exosomes from IL-1β-stimulated SFB than in HUVEC incubated with PBS and the exosomes from non-stimulated SFB. Data
are the means ± SEM. Comparison of mean values was performed by the Steel test; *P <0.05 versus control. Cont, isolated exosomes from
fresh-DMEM with 10% FBS; Exo -IL-1β, exosomes from non-stimulated SFB; Exo + IL-1β, exosomes from IL-1β stimulated SFB; Cont, control.
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via OA-like signals such as catabolic and angiogenic sig-
nals to joint tissues.
miRNA are small noncoding RNA of 1 to 25 nucleo-
tides that repress the translation of and/or cleave mRNA
by partially base-pairing with the untranslated regions
and/or coding regions of their target transcripts [44].
Therefore, miRNA can silence the expression of multiple
genes [44]. Several miRNA, such as miR-140, are associ-
ated with OA pathogenesis [7,45,46]. Although previous
studies have focused on intracellular miRNA, miRNA
have recently been identified in several extracellular
compartments. Exosomes contain proteins, mRNA andmiRNA, and protect miRNA from RNase [26,36], and
miRNA can be transferred between tissues and even be-
tween individuals via biological fluids [16,26]. However,
it is reported that the extracellular miRNA in blood
plasma and cell culture is independent from exosomes
and is bound to Ago2 protein, a part of RNA-induced si-
lencing complex [47,48]. Thus, we may have identified
extracellular miRNA rather than miRNA in exosomes.
IL-1β stimulation of SFB increased the amount of re-
leased exosomes from SFB. Furthermore, the IL-1β
stimulation altered the miRNA expression pattern not
only in SFB but also in released exosomes. Although
most of the upregulated miRNAs in IL-1β-stimulated
Figure 7 Identification of miRNAs in exosomes from synovial fibroblasts (SFB). (A) Expression profiling of 800 human miRNA in SFB with
IL-1β or without IL-1β, and exosomes from IL-1β-stimulated or non-stimulated SFB: 340 miRNA were upregulated and 24 miRNA downregulated
in IL-1β-stimulated SFB, and 11 miRNA were upregulated and 39 miRNA downregulated in exosomes from IL-1β-stimulated SFB. (B) Venn diagram
comparing miRNA in IL-1β-stimulated SFB and exosomes from IL-1β-stimulated SFB. Five miRNA commonly presented in IL-1β-stimulated SFB
and exosome from IL-1β-stimulated SFB, and six miRNA selectively presented in exosomes. (C) Differentially upregulated miRNA (2-fold difference)
are shown as the ratio of exosomes from IL-1β-stimulated SFB to exosomes from non-stimulated SFB. Values for miRNA in exosomes from IL-1β
stimulated SFB and exosomes from non-stimulated SFB are miRNA levels (nanostring code count). *miRNAs were not expressed in SFB.
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http://arthritis-research.com/content/16/4/R163SFB were also upregulated in their exosomes, several
miRNA were identified only in exosomes. This result
suggests a selective mechanism of miRNA release from
cells. Indeed, although several studies reported these
findings [26,38-40,49,50], this mechanism is not still
well-understood. Among upregulated miRNA (>2-fold)
in exosomes from IL-1β-stimulated SFB, six miRNA
were selectively present in exosomes. MiRNA in
condition-specific exosomes may function as a unique
set of miRNA. These results suggest that miRNA may
not only function as regulatory molecules within cells
such as SFB and chondrocytes, but also as components
of exosomes contributing to OA pathogenesis by medi-
ating cell-cell and tissue-tissue communication in osteo-
arthritic joints. Future studies need to determine the
amount of exosomes released from non-OA- and OA-
derived tissues and from cells, and the amount presentin synovial fluid, and to identify the messenger mole-
cules in exosomes that mediate the observed effects on
chondrocytes.
Conclusions
The present results show that SFB secrete exosomes,
and IL-1β-stimulated SFB release increased the numbers
of exosomes compared with non-stimulated SFB.
miRNA are selectively presented in the exosomes. Exo-
somes from IL-1β-stimulated SFB lead to OA-like
changes in gene expression patterns in human articular
chondrocytes, and cartilage degradation. In addition,
these exosomes stimulated angiogenic activity. SFB-
derived exosomes may be involved in OA pathogenesis
by stimulating gene expression in articular chondrocytes,
and promoting angiogenesis. Our observations suggest
that not only established signaling molecules, such as
Kato et al. Arthritis Research & Therapy 2014, 16:R163 Page 10 of 11
http://arthritis-research.com/content/16/4/R163cytokines and hormones, but also exosomes including
miRNA, as mediators of communication among differ-
ent joint cells and tissues play an important role in OA
pathogenesis as a new regulatory mechanism.
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